젬시타빈 염산염 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 11억 달러 규모로 성장할 것으로 예상되며, 7.0%의 연평균 성장률을 기록할 것으로 예상됩니다. 예측 기간의 성장은 전 세계 암 발병률 증가, 고령화, 비소세포폐암 발병률 증가, 췌장암 및 전이성 유방암 사례의 급증, 병용 화학요법 대상 환자 수 증가에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 새로운 약물의 조합 및 적응증을 검토하는 진행 중인 임상시험, 시스플라틴, 카보플라틴, 파클리탁셀을 포함한 약제와의 병용요법에서의 사용 확대, 약물전달 시스템의 발전, 독성 감소를 위한 제제 기술의 개선, 의약품 제조 공정의 자동화 등이 있습니다. 공정 자동화의 발전 등을 들 수 있습니다.
유방암 발병률의 증가는 향후 몇 년 동안 젬시타빈 염산염 시장의 성장을 촉진할 것으로 예상됩니다. 유방암은 일반적으로 유방의 세포, 일반적으로 유관과 유선에서 발생합니다. 평균 수명이 증가함에 따라 유방암의 위험도 증가하는데, 이는 주로 나이가 들어감에 따라 유전자 돌연변이가 축적될 가능성이 높아지기 때문입니다. 젬시타빈 염산염은 DNA 복제를 억제하여 비정상적인 세포의 급속한 증식을 늦추는 유방암 치료에 중요한 역할을 합니다. 예를 들어, 2024년 9월 호주 정부는 2022년 호주에서 약 2,640명이 유방암 진단을 받을 것으로 예상되며, 85세까지 유방암 진단을 받을 평생 위험은 남성의 경우 15명 중 1명(6.7%) - 668명 중 1명(0.15%), 여성의 경우 8명 중 1명(13%)로 예측되었습니다. 이러한 유병률 증가는 젬시타빈 염산염을 포함한 효과적인 치료제에 대한 수요 증가를 강조하고 있습니다.
젬시타빈 염산염 시장의 주요 업체들은 수술 전후 면역요법과 같은 혁신적인 접근법을 개발하여 암 치료의 성과를 개선함으로써 암 치료를 발전시키고 있습니다. 수술 전후 면역요법은 수술 전(신보조요법)과 수술 후(보조요법) 모두에서 치료 효과를 높이고 암의 재발 위험을 낮추기 위한 치료법입니다. 예를 들어, 2025년 3월 영국 제약회사 아스트라제네카(AstraZeneca)는 미국 식품의약국(FDA)으로부터 임핀지(durvalumab)를 승인받아 근층침윤성 방광암(MIBC)에 대한 최초이자 유일하게 승인된 수술 전후 면역요법이 되었습니다. 이 치료 프로토콜은 수술 전 임핀지와 화학요법제(젬시타빈 및 시스플라틴)를 병용하고, 수술 후에도 임핀지를 계속 사용하는 방식입니다. 임상시험에서 이 병용요법이 생존율을 유의하게 개선하고 재발 가능성을 감소시키는 것으로 입증되어 암 치료에서 이러한 병용요법의 혁신적 가능성을 강조했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 젬시타빈 염산염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 젬시타빈 염산염 시장 : 성장률 분석
- 세계의 젬시타빈 염산염 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 젬시타빈 염산염 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 젬시타빈 염산염 전체 시장(TAM)
제6장 시장 세분화
- 세계의 젬시타빈 염산염 시장 : 제품 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 주사
- 솔루션
- 기타 제품 유형
- 세계의 젬시타빈 염산염 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 정맥주사
- 피하주사
- 근육내 주사
- 세계의 젬시타빈 염산염 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원 약국
- 소매 약국
- 온라인 약국
- 전문 클리닉
- 세계의 젬시타빈 염산염 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 췌장암
- 비소세포폐암
- 방광암
- 유방암
- 난소암
- 기타 용도
- 세계의 젬시타빈 염산염 시장, 주사 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 일회 투여 바이알
- 멀티 도스 바이알
- 프리필드 시린지
- 세계의 젬시타빈 염산염 시장, 솔루션 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 곧바로 사용할 수 있는 액체 용액
- 희석용 농축 용액
- 경구 액제
- 세계의 젬시타빈 염산염 시장, 기타 제품 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 동결건조 분말
- 캡슐
- 기타 화학요법제와의 병용 제제
제7장 지역별·국가별 분석
- 세계의 젬시타빈 염산염 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 젬시타빈 염산염 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 젬시타빈 염산염 시장 : 경쟁 구도
- 젬시타빈 염산염 시장 : 기업 개요
- Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis
- Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Mylan NV Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Accord Healthcare
- Sandoz Group AG
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
- Dr. Reddy's Laboratories
- Cipla Ltd.
- Amneal Pharmaceuticals
- Alkem Laboratories
- Gland Pharma Ltd.
- Strides Pharma Science Ltd.
- Shilpa Medicare Ltd.
- ScinoPharm Taiwan Ltd.
- Orchid Pharma Ltd.
- Arevipharma GmbH
- Qilu Pharmaceutical Co. Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 젬시타빈 염산염 시장 2029년 : 새로운 기회를 제공하는 국가
- 젬시타빈 염산염 시장 2029년 : 새로운 기회를 제공하는 부문
- 젬시타빈 염산염 시장 2029년 : 성장 전략
제36장 부록
ksm
Gemcitabine hydrochloride is a synthetic nucleoside analog that disrupts DNA synthesis, thereby preventing cell division. Due to its ability to integrate into DNA strands and halt replication, it is widely used in research focused on cellular replication. Once inside the cell, gemcitabine is phosphorylated into its active form, becomes incorporated into DNA, causes chain termination, and ultimately initiates programmed cell death.
The primary product types of gemcitabine hydrochloride include injections, solutions, and other forms. The injection form is delivered directly into the bloodstream using a syringe or intravenous (IV) method and may also be administered subcutaneously or intramuscularly. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. It is used in the treatment of various cancers, including pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and others.
The gemcitabine hydrochloride market research report is one of a series of new reports from The Business Research Company that provides gemcitabine hydrochloride market statistics, including gemcitabine hydrochloride industry global market size, regional shares, competitors with a gemcitabine hydrochloride market share, detailed gemcitabine hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the gemcitabine hydrochloride industry. This gemcitabine hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gemcitabine hydrochloride market size has grown strongly in recent years. It will grow from $0.78 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to several factors, including the expansion of early-stage cancer detection programs, the development of oncology drug distribution networks, increased access to treatment through both public and private healthcare systems, greater inclusion of gemcitabine hydrochloride in hospital oncology formularies, and a general rise in global healthcare expenditures.
The gemcitabine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.10 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The projected growth in the forecast period can be attributed to the increasing global prevalence of cancer, an aging population, a rising incidence of non-small cell lung cancer, a surge in pancreatic and metastatic breast cancer cases, and a growing number of patients eligible for combination chemotherapy. Key trends expected during this period include ongoing clinical trials investigating new drug combinations and indications, expanded use in combination therapies with agents including cisplatin, carboplatin, and paclitaxel, advancements in drug delivery systems, improved formulation technologies aimed at reducing toxicity, and increased automation in pharmaceutical manufacturing processes.
The increasing incidence of breast cancer is expected to drive the growth of the gemcitabine hydrochloride market in the coming years. Breast cancer originates in the cells of the breast, typically within the milk ducts or glands. As life expectancy rises, the risk of breast cancer also increases, primarily due to the greater likelihood of genetic mutations accumulating with age. Gemcitabine hydrochloride plays a vital role in breast cancer treatment by disrupting DNA replication, thereby slowing the rapid proliferation of abnormal cells. For example, in September 2024, the Australian Government reported that an estimated 20,640 individuals in Australia were expected to be diagnosed with breast cancer in 2022, including 212 males and 20,428 females. The overall lifetime risk of being diagnosed with breast cancer by age 85 was projected at 1 in 15 (6.7%)-1 in 668 (0.15%) for men and 1 in 8 (13%) for women. This rising prevalence underscores the growing demand for effective treatments, including gemcitabine hydrochloride.
Leading companies in the gemcitabine hydrochloride market are advancing cancer treatment by developing innovative approaches such as perioperative immunotherapy to improve therapeutic outcomes. Perioperative immunotherapy involves administering treatment both before (neoadjuvant) and after (adjuvant) surgery to enhance effectiveness and lower the risk of cancer recurrence. For example, in March 2025, AstraZeneca, a UK-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Imfinzi (durvalumab), marking it as the first and only approved perioperative immunotherapy for muscle-invasive bladder cancer (MIBC). The treatment protocol includes a combination of Imfinzi with chemotherapy agents-gemcitabine and cisplatin-prior to surgery, followed by continued use of Imfinzi post-surgery. Clinical trials demonstrated that this approach significantly improved survival rates and reduced the includinglihood of recurrence, highlighting the transformative potential of such combination therapies in oncology.
In December 2024, Cheplapharm, a pharmaceutical company based in Germany, acquired Gemzar from Eli Lilly for an undisclosed amount. This acquisition enhances Cheplapharm's oncology portfolio by adding Gemzar, a well-established chemotherapy drug used to treat a range of cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer. Eli Lilly and Company is a US-based manufacturer of gemcitabine hydrochloride, commonly known as Gemzar.
Major players in the gemcitabine hydrochloride market are Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Mylan NV, Accord Healthcare, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy's Laboratories, Cipla Ltd., Amneal Pharmaceuticals, Alkem Laboratories, Gland Pharma Ltd., Strides Pharma Science Ltd., Shilpa Medicare Ltd., ScinoPharm Taiwan Ltd., Orchid Pharma Ltd., Arevipharma GmbH, and Qilu Pharmaceutical Co. Ltd.
North America was the largest region in the gemcitabine hydrochloride market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gemcitabine hydrochloride report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gemcitabine hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gemcitabine hydrochloride market consists of sales of pharmaceutical intermediates, generic injectable drugs, and formulation development kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gemcitabine Hydrochloride Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gemcitabine hydrochloride market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gemcitabine hydrochloride ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gemcitabine hydrochloride market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Type: Injection; Solution; Other Product Types
- 2) By Route of Administration: Intravenous Injection; Subcutaneous Injection; Intramuscular Injection
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics
- 4) By Application: Pancreatic Cancer; Non-Small Cell Lung Cancer; Bladder Cancer; Breast Cancer; Ovarian Cancer; Other Applications
- Subsegments:
- 1) By Injection: Single-Dose Vials; Multi-Dose Vials; Prefilled Syringes
- 2) By Solution: Ready-To-Use Liquid Solutions; Concentrated Solutions For Dilution; Oral Liquid Formulations
- 3) By Other Product Types: Lyophilized Powder; Capsules; Combination Formulations With Other Chemotherapeutic Agents
- Companies Mentioned: Fresenius Kabi; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd.; Mylan NV
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gemcitabine Hydrochloride Market Characteristics
3. Gemcitabine Hydrochloride Market Trends And Strategies
4. Gemcitabine Hydrochloride Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Gemcitabine Hydrochloride Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gemcitabine Hydrochloride PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gemcitabine Hydrochloride Market Growth Rate Analysis
- 5.4. Global Gemcitabine Hydrochloride Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gemcitabine Hydrochloride Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gemcitabine Hydrochloride Total Addressable Market (TAM)
6. Gemcitabine Hydrochloride Market Segmentation
- 6.1. Global Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injection
- Solution
- Other Product Types
- 6.2. Global Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous Injection
- Subcutaneous Injection
- Intramuscular Injection
- 6.3. Global Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- 6.4. Global Gemcitabine Hydrochloride Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
- Bladder Cancer
- Breast Cancer
- Ovarian Cancer
- Other Applications
- 6.5. Global Gemcitabine Hydrochloride Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single-Dose Vials
- Multi-Dose Vials
- Prefilled Syringes
- 6.6. Global Gemcitabine Hydrochloride Market, Sub-Segmentation Of Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ready-To-Use Liquid Solutions
- Concentrated Solutions For Dilution
- Oral Liquid Formulations
- 6.7. Global Gemcitabine Hydrochloride Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Lyophilized Powder
- Capsules
- Combination Formulations With Other Chemotherapeutic Agents
7. Gemcitabine Hydrochloride Market Regional And Country Analysis
- 7.1. Global Gemcitabine Hydrochloride Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gemcitabine Hydrochloride Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gemcitabine Hydrochloride Market
- 8.1. Asia-Pacific Gemcitabine Hydrochloride Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gemcitabine Hydrochloride Market
- 9.1. China Gemcitabine Hydrochloride Market Overview
- 9.2. China Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gemcitabine Hydrochloride Market
- 10.1. India Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gemcitabine Hydrochloride Market
- 11.1. Japan Gemcitabine Hydrochloride Market Overview
- 11.2. Japan Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gemcitabine Hydrochloride Market
- 12.1. Australia Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gemcitabine Hydrochloride Market
- 13.1. Indonesia Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gemcitabine Hydrochloride Market
- 14.1. South Korea Gemcitabine Hydrochloride Market Overview
- 14.2. South Korea Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gemcitabine Hydrochloride Market
- 15.1. Western Europe Gemcitabine Hydrochloride Market Overview
- 15.2. Western Europe Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gemcitabine Hydrochloride Market
- 16.1. UK Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gemcitabine Hydrochloride Market
- 17.1. Germany Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gemcitabine Hydrochloride Market
- 18.1. France Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gemcitabine Hydrochloride Market
- 19.1. Italy Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gemcitabine Hydrochloride Market
- 20.1. Spain Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gemcitabine Hydrochloride Market
- 21.1. Eastern Europe Gemcitabine Hydrochloride Market Overview
- 21.2. Eastern Europe Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gemcitabine Hydrochloride Market
- 22.1. Russia Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gemcitabine Hydrochloride Market
- 23.1. North America Gemcitabine Hydrochloride Market Overview
- 23.2. North America Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gemcitabine Hydrochloride Market
- 24.1. USA Gemcitabine Hydrochloride Market Overview
- 24.2. USA Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gemcitabine Hydrochloride Market
- 25.1. Canada Gemcitabine Hydrochloride Market Overview
- 25.2. Canada Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gemcitabine Hydrochloride Market
- 26.1. South America Gemcitabine Hydrochloride Market Overview
- 26.2. South America Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gemcitabine Hydrochloride Market
- 27.1. Brazil Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gemcitabine Hydrochloride Market
- 28.1. Middle East Gemcitabine Hydrochloride Market Overview
- 28.2. Middle East Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gemcitabine Hydrochloride Market
- 29.1. Africa Gemcitabine Hydrochloride Market Overview
- 29.2. Africa Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gemcitabine Hydrochloride Market Competitive Landscape And Company Profiles
- 30.1. Gemcitabine Hydrochloride Market Competitive Landscape
- 30.2. Gemcitabine Hydrochloride Market Company Profiles
- 30.2.1. Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Mylan NV Overview, Products and Services, Strategy and Financial Analysis
31. Gemcitabine Hydrochloride Market Other Major And Innovative Companies
- 31.1. Accord Healthcare
- 31.2. Sandoz Group AG
- 31.3. Sun Pharmaceutical Industries Ltd.
- 31.4. Apotex Inc.
- 31.5. Dr. Reddy's Laboratories
- 31.6. Cipla Ltd.
- 31.7. Amneal Pharmaceuticals
- 31.8. Alkem Laboratories
- 31.9. Gland Pharma Ltd.
- 31.10. Strides Pharma Science Ltd.
- 31.11. Shilpa Medicare Ltd.
- 31.12. ScinoPharm Taiwan Ltd.
- 31.13. Orchid Pharma Ltd.
- 31.14. Arevipharma GmbH
- 31.15. Qilu Pharmaceutical Co. Ltd.
32. Global Gemcitabine Hydrochloride Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gemcitabine Hydrochloride Market
34. Recent Developments In The Gemcitabine Hydrochloride Market
35. Gemcitabine Hydrochloride Market High Potential Countries, Segments and Strategies
- 35.1 Gemcitabine Hydrochloride Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gemcitabine Hydrochloride Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gemcitabine Hydrochloride Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
